Cadrenal Therapeutics, Inc. (CVKD): Capital Expenditures
$5.1K
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.1K | -21.9% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $6.5K | +100.9% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $3.3K | n/a | 2025-03-13, From 2023-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | 2025-12-31 | $5.1K | -21.9% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $24.6K | -42.7% |
| Pulmatrix, Inc. (PULM) | 2024-12-31 | $398.0K | -41.1% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $43.0K | -74.1% |
| Azitra, Inc. (AZTR) | 2025-12-31 | $24.2K | +182.6% |
| Protagenic Therapeutics, Inc.\new (PTIX) | 2026-03-31 | $3.3K | n/a |
| Petros Pharmaceuticals, Inc. (PTPI) | 2024-12-31 | $24.6K | n/a |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $1.2K | -98.8% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $139.9K | +34.8% |
Compare CVKD, LEXX, PULM, ISCO side by side · Screen every company in Pharmaceutical Preparations ↗